Jun 2026 (Q2 FY26) — Aug 10, 2026
Tonix Pharmaceuticals Q2 FY26 — Strong Tonmaya Sales Growth and Pipeline Progress
Read the full callTonix Pharmaceuticals (TNXP) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tonix Pharmaceuticals earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 13.5 | +577.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -314.1 | +1102.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -40.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$6.04 −5.92% · −$0.38
Performance −69.0% 1Y
1Y: $19.5 on 15 Oct 2025 → $6.04. High $20.35 (27 Oct 2025), low $6.04 (16 Oct 2026).
- Previous close
- $6.42
- 52-week range
- $6.04 – $20.35
- One year
- −67.89%
Overview
- Symbol
- TNXP
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Tonix Pharmaceuticals earnings calls (TNXP)
Financials
What the filings say
Net profit, year on year: −43% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 3 | 2 | 2 | 3 | 5 | 7 | 14 |
| Expenses | 18 | 25 | 18 | 30 | 36 | 54 | 48 | 56 |
| Operating profit | -16 | -22 | -16 | -28 | -33 | -48 | -42 | -43 |
| Operating margin | −551.2% | −870.6% | −660.9% | −1416.2% | −1005.1% | −895.8% | −603.9% | −314.1% |
| Interest | 0 | 0 | — | — | — | 0 | — | — |
| Net profit | -14 | -22 | -17 | -28 | -32 | -47 | -40 | -41 |
| EPS ($ per share) | -22.68 | — | -2.84 | -3.86 | -3.59 | — | -2.93 | -2.44 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -188 | -217 | -268 | -360 | -470 | -601 | -731 | -855 |
| Total liabilities | 3 | 5 | 11 | 22 | 19 | 49 | 23 | 32 |
| Fixed assets | 0 | 0 | 9 | 51 | 94 | 94 | 42 | 44 |
| Total assets | 26 | 15 | 98 | 241 | 226 | 154 | 163 | 277 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24 | -27 | -49 | -76 | -98 | -102 | -61 | -100 |
| Cash from investing | -0 | -0 | -9 | -35 | -48 | -29 | -0 | -5 |
| Cash from financing | 24 | 13 | 123 | 212 | 88 | 37 | 135 | 215 |
| Net cash flow | -0 | -14 | 66 | 102 | -58 | -95 | 74 | 110 |
| Capital expenditure | -0 | -0 | -9 | -35 | -48 | -8 | -0 | -3 |
| Free cash flow | -24 | -27 | -57 | -111 | -146 | -110 | -61 | -103 |
Insider filings
8 filings between Mar 18, 2026 and Aug 27, 2026.
Open market
decisions to buy or sellPurchases
$458.8K
7 purchases by 4 insiders
Sales
None
No insider sold shares.
Also filed: 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| LEDERMAN SETH | $373.0K | — | Aug 27, 2026 |
| Stillwell Richard Newcomb | $58.3K | — | Jun 8, 2026 |
| Taylor Carolyn E. | $14.9K | — | Jun 12, 2026 |
| BAGGER RICHARD H | $12.6K | — | Aug 20, 2026 |
Latest filings (21)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2026 | LEDERMAN SETH Chief Executive Officer | Purchase | 2,000 | $27.6K |
| Aug 20, 2026 | BAGGER RICHARD H Director | Purchase | 1,000 | $12.6K |
| Jun 30, 2026 | SAENGER BRADLEY Chief Financial Officer | Other | 1,453 | $15.9K |
| Jun 12, 2026 | Taylor Carolyn E. Director | Purchase | 1,415 | $14.9K |
| Jun 9, 2026 | LEDERMAN SETH Chief Executive Officer | Purchase | 5,000 | $58.9K |
| Jun 8, 2026 | Stillwell Richard Newcomb Director | Purchase | 5,000 | $58.3K |
| Mar 31, 2026 | LEDERMAN SETH Chief Executive Officer | Purchase | 5,000 | $63.1K |
| Mar 18, 2026 | LEDERMAN SETH Chief Executive Officer | Purchase | 15,000 | $223.3K |
| Aug 21, 2025 | Taylor Carolyn E. Director | Purchase | 418 | $15.1K |
| Aug 20, 2025 | Treco James Director | Purchase | 250 | $9.0K |
| May 15, 2025 | LEDERMAN SETH Chief Executive Officer | Purchase | 4,000 | $86.2K |
| Feb 5, 2025 | Treco James Director | Other | 0 | $0 |
| Feb 5, 2025 | Bell Margaret Smith Director | Other | 1 | $0 |
| Feb 5, 2025 | BAGGER RICHARD H Director | Other | 0 | $0 |
| Feb 5, 2025 | LEDERMAN SETH Chief Executive Officer | Other | 0 | $1 |
| Feb 5, 2025 | LEDERMAN SETH Chief Executive Officer | Other | 1 | $0 |
| Feb 5, 2025 | MORRIS JESSICA EDGAR Chief Operating Officer | Other | 1 | $0 |
| Feb 5, 2025 | LEDERMAN SETH Chief Executive Officer | Other | 5 | $18 |
| Feb 5, 2025 | SULLIVAN GREGORY M Chief Medical Officer | Other | 0 | $0 |
| Feb 5, 2025 | SAENGER BRADLEY Chief Financial Officer | Other | 0 | $0 |
| Jun 10, 2024 | OLUKOTUN ADEOYE Y Director | Other | 1 | $2 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Tonix Pharmaceuticals Holding Corp.
Free account. Everything above stays public.
Write why you follow Tonix Pharmaceuticals Holding Corp. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading